**WPSD Quiz – 2025 - Engels**

1. Which special situation does not need to be reported to PV?
	1. Drug exposure during pregnancy and/or breastfeeding
	2. Lack of efficacy
	3. Medication error, e.g. forget one injection
	4. Stopped with therapy
2. How many ICSRs (Individual Case Safety Reports) did Lareb receive from pharmaceutical companies in 2024?
	1. Around 8.000
	2. Around 13.000
	3. Around 20.000
	4. Around 28.000
3. How many adverse events were submitted to the health authority by [company name] in Q2 2025?
**OR**
At [company name] we received [xxx] adverse events during the period of [H1 2025/Q2 2025]. How many of those were reported by you and your colleagues?
(retrieve a report from the safety database and add your own numbers)
	1. X
	2. X
	3. X
	4. X
4. What is the primary theme for the WHO World Patient Safety Day 2025?
	1. Patient safety from the start
	2. Safe care for every newborn and every child
	3. Improving diagnosis for Patient Safety
	4. Working together to make health care safer
5. Redness of the skin is a common adverse event for injections and is also stated in the package leaflet. If you receive such an adverse event, you need to report it to PV.
	1. True
	2. False
6. Additional risk minimisation measures (aRMM) are sometimes required to manage the risks and/or strengthen the positive benefit-risk profile of a medicinal product.
For which products do we have aRMM at [company name]? (enter the products for which your organization has aRMM in place)
	1. X
	2. X
	3. X
	4. X
7. What is the well-recognized signature mark color of the World Patient Safety Day campaign?
	1. Red
	2. Green
	3. Blue
	4. Orange
8. Which building in the Netherlands is illuminated in the signature color of World Patient Safety Day, on 17 September 2025?
	1. Erasmusbrug
	2. Rijksmuseum
	3. Wereldmuseum
	4. Domtoren
9. How can you report an adverse event to PV? (multiple options possible) (adjust this question based on the various reporting options in your organization)
	1. Send an email to ‘drugsafetyx@x.com’
	2. Use the application ‘name app’
	3. Via the website [www.lareb.nl](https://www.lareb.nl)
	4. Call to the following number ‘x’
10. How does pharmacovigilance contribute to safer medication use in newborns and children?
11. It ensures that medicines used in children are prescribed only by pediatric specialists.
12. It supports the development of child-specific formulations by pharmaceutical companies.
13. It monitors and analyzes adverse events in children to improve knowledge resulting in more adequate product information.
14. It prevents off-label use through regulatory enforcement.
15. Which of the following best describes the role of adverse event reporting in improving pediatric medication safety?
	1. It is only useful when adverse events are reported by physicians.
	2. It helps identify safety signals in real-world use, especially in populations like children who are underrepresented in clinical trials.
	3. It replaces the need for pediatric clinical trials.
	4. It is mainly used for marketing purposes.